Prolia's sales amounted to ₩75.1 billion in 4 years

59% increase from the previous year, sales of Evenity was ₩3.8 billion

Bisphosphonate sales fell at once, Forsteo fell 21% and Foosamax 15%

Prolia

Amgen's Prolia (Denosumab) ranked first in the osteoporosis treatment market.

 

Amgen's Evenity (Romosozumab) is expected to start earning sales this year.

 

Amgen, which has established a lineup leading to Evenity-Prolia in the osteoporosis treatment market, is expected to sustain high sales for some time.

 

Most of the bisphosphonates, which had previously led the market, declined after the launch of Prolia.

 

◆Prolia's sales increased 59% in one year from ₩47.3 billion to ₩75.1 billion According to IQVIA on the 23rd, Prolia's sales last year amounted to ₩75.1 billion.

 

Compared to ₩47.3 billion in 2019, it increased by 59%.

 

Amgen released Prolia in Korea in November 2016.

 

In October 2017, it became a reimbursement drug, but it was limited to secondary treatment and quarterly sales remained at the level of ₩2~4 billion.

 

Sales began to increase in earnest as it expanded to primary treatment in April 2019.

 

Sales from ₩4.9 billion in the first quarter of 2019 rose to ₩12.3 billion in the second quarter.

 

The maximum insurance price has decreased by 12% from ₩215,678 (per vial) to ₩190,000.

 

From the second quarter of 2020, it posted sales of ₩20 billion every quarter.

 

In the second quarter, it was ₩20.5 billion, ₩20 billion in the third quarter, and ₩20.2 billion in the fourth quarter.

 

In December of last year, Prolia's upper limit price was cut again.

 

Because it sold too much.

 

The MOHW cut the upper limit of Prolia by 6.5% from ₩190,000 to ₩170,650 on December 4 of last year according to the Price-volume agreement.

 

It is analyzed that the expansion of benefits and strengthening of sales power contributed to the growth of Prolia.

 

Amgen has been selling Prolia with Chong Kun Dang since September 2017.

 

Amgen Korea is in charge of sales and marketing of Prolia in general hospitals and Chong Kun-dang in semi-general hospitals and clinics.

 

◆Forsteo, Bonviva, and Fosamax sales fell Most of the major osteoporosis treatments that were leading the market showed a decline in sales.

 

Sales of Forsteo by Eli Lilly, which occupied the first place in the market before the launch of Prolia, fell 21% from ₩21.7 billion in 2019 to ₩17.1 billion last year.

 

Sales of bisphosphonate treatments declined similarly.

 

In the case of Bonviva and Bonviva plus by Handok, the total sales decreased by 5% from ₩14 billion to ₩13.3 billion.

 

The sales of Fosamax by MSD also decreased by 16% from ₩14.3 billion to ₩12.2 billion, and sales of Daewoong's Zoledronic acid fell 21% from ₩14.1 billion to ₩11.2 billion.

 

Excluding Amgen's treatment, Hanmi's RaboneD rose in sales.

 

SERM-based treatment, RaboneD (Raloxifene/Cholecalciferol), increased sales by 7% from ₩8.5 billion in 2019 to ₩9.1 billion last year.

 

◆Amgen's Evenity From this year, Evenity will enter a new competitive drug.

 

Evenity, a follow-up to Prolia by Amgen, were reimbursed in December of last year.

 

Evenity is a bone-forming agent with dual effects of promoting bone formation and inhibiting bone resorption.

 

Amgen is planning Evenity's positioning strategy in the order of Evenity→Prolia.

 

Amgen has conducted clinical trials for Evenity in a sequential dosage method.

 

In patients with high risk of fracture, after taking Evenity to prolia, and for additional treatment for 12 months, the Evenity-prolia treatment group lowered the risk of new vertebral fractures by 75% compared to the placebo-prolia treatment group.

 

Evenity has recorded sales of around ₩1 billion after its release in December 2019, even though it was before benefits.

 

Evenity's total sales last year was ₩3.8 billion.

 

Amgen expects that sales will start in earnest from this year following the application of the benefits at the end of last year.

 

Amgen also sells Evenity with Chong Kun Dang as well as Prolia.